Bone Biologics Co. Forecasted to Earn Q3 2024 Earnings of ($0.60) Per Share (NASDAQ:BBLG)

Bone Biologics Co. (NASDAQ:BBLG) – Research analysts at Zacks Small Cap lifted their Q3 2024 earnings estimates for Bone Biologics in a report released on Monday, August 12th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.60) for the quarter, up from their previous estimate of ($1.34). The consensus estimate for Bone Biologics’ current full-year earnings is ($5.32) per share. Zacks Small Cap also issued estimates for Bone Biologics’ Q4 2024 earnings at ($0.59) EPS, FY2024 earnings at ($3.17) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.19) EPS and FY2026 earnings at ($2.21) EPS.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($1.39) by $0.72.

Bone Biologics Stock Up 6.5 %

Shares of NASDAQ BBLG opened at $1.47 on Wednesday. The business has a 50-day moving average of $1.49 and a 200-day moving average of $2.00. Bone Biologics has a 1-year low of $1.00 and a 1-year high of $10.64.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.